The Billion-Dollar Seed Isn't The Deal You Think It Is
Despite attention-grabbing AI mega-seed rounds, historical data shows that very large first financings rarely produce venture-scale returns because high entry valuations limit investor upside. Instead, argues guest author Ellie McDonald, the strongest venture outcomes have typically come from capital-efficient startups that raised modest early rounds. Guest Author By Ellie McDonald Everywhere you look, venture headlines imply that seed rounds have meaningfully changed shape.
Key Takeaways
- Yann LeCun raised $1 billion for a company that didn't exist a week earlier.
- and a very long tail of modest ones.
Our experience with this trend in biotech motivated us to compile a dataset and pressure-test our intuition more broadly.
- But even there, the return math is nuanced for first round investors.
According to reports, first-round investors are looking at 30-40x returns at OpenAI's projected IPO valuations.
- Those historical investors got in at a price that left room for the upside to actually compound.
The mega round is real, but not replacing the market The number of $50 million-plus seed rounds has exploded since 2018.
- Cursor at less than $10 million is the more representative data point.
Stats & Key Facts
- #Yann LeCun raised $1 billion for a company that didn't exist a week earlier.
- #Unconventional AI hit $475 million two months after founding.
- #Biotech mega-seeds are common because the science requires it, you can't run a Phase 1 trial on $3 million, but the return profile is often humbling.
- #We pulled every publicly available $100 million-plus first round we could find over the last 15 years (roughly 200 deals) and found that only 20% had recorded exits.
It's easy to read those headlines and conclude the venture model has been rewritten, that AI is a once-in-a-generation opportunity requiring once-in-a-generation capital. The biotech parallel At Bison Ventures , we've built deep domain expertise in biotech, the sector with the longest history of mega first rounds in venture. Biotech mega-seeds are common because the science requires it, you can't run a Phase 1 trial on $3 million, but the return profile is often humbling.
Large first rounds in biotech have produced a handful of strong outcomes for first-check investors ... and a very long tail of modest ones. Our experience with this trend in biotech motivated us to compile a dataset and pressure-test our intuition more broadly.
We pulled every publicly available $100 million-plus first round we could find over the last 15 years (roughly 200 deals) and found that only 20% had recorded exits. Of those, only a few delivered what we'd call a venture-like return: 10x MOIC or better for the first-round investor. In other words, approximately 1% of companies that publicly raised $100 million or more in their first financing round generated returns that justify the asset class.
For more details please read the original article at Crunchbase News.
Continue Learning
Comments
Sign in to join the conversation